The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Editorial
PreviousPrevious
Volume 337:195-197 July 17, 1997 Number 3
NextNext

Anticytokine Therapy in Rheumatoid Arthritis

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
Only a few years ago, little was known about the role of cytokines in rheumatoid arthritis. The original view of the cytokine milieu in the inflamed joint as a melange of factors from various cells was clarified by two observations.1 First, in inflammation of rheumatoid arthritis, cytokines from macrophages and fibroblasts dominate, and second, the cytokine profile within the macrophage and fibroblast reflects a hierarchy, with interleukin-1 and tumor necrosis factor {alpha} (TNF-{alpha}) assuming particular importance. Anticytokine therapy for rheumatoid arthritis has now reached the clinic, and the report in this issue of the Journal by Moreland et al.2 adds . . . [Full Text of this Article]

References


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.